FIELD: medicine.
SUBSTANCE: invention refers to prevention and treatment of pancreatic diabetes type 2. To delay disease development or to provide early stage treatment such inhibitors of dipeptidylpeptidase IV are selected as to supply optimal inhibition constant. For this purpose (2S)-1 -((2'S)-2' -amino-3' ,3' -dimethylbutanoil) pyrrolidine-2-carbonitryl or its pharmaceutically accepted salt, or (2S)-l-((2'S)-2'-amino-5'-pyrazincarbonylaminopentanoil)pyrrolidine-2-carbonitryl or its pharmaceutically accepted salt.
EFFECT: improved prevention of diabetes and related complications.
3 cl, 7 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FERTILITY IMPROVING COMPOSITIONS | 2000 |
|
RU2246944C2 |
| NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND USES THEREOF AS HYPOTENSIVE AGENT | 2002 |
|
RU2305553C2 |
| THERAPEUTIC DRUG OR PREVENTIVE THERAPEUTIC AGENT FOR DIABETIC NEPHROPATHY | 2017 |
|
RU2735538C1 |
| APPLICATION OF DIPEPTIDYLPEPTIDASE IV INHIBITORS | 2004 |
|
RU2385723C2 |
| DPP-IV INHIBITORS FOR TREATMENT OF NEURODEGENERATION AND COGNITIVE DISORDERS | 2005 |
|
RU2394570C2 |
| USE OF SIGMA LIGANDS IN DIABETES TYPE-2 ASSOCIATED PAIN | 2012 |
|
RU2608943C2 |
| COMBINATION OF DIPEPTIDILPEPTIDASE IV (DPP IV) INHIBITOR AND CARDIOVASCULAR SUBSTANCE | 2003 |
|
RU2336876C2 |
| METHOD FOR IMPROVING SIGNAL TRANSFER IN ISLETS OF LANGERHANS IN DIABETES MELLITUS AND IN ITS PROPHYLAXIS | 2001 |
|
RU2261096C2 |
| THERAPEUTIC AGENT CONTAINING COMBINED USE OF COMBINATION OF DPP-IV INHIBITOR AND OTHER THERAPEUTIC AGENT FOR TREATING DIABETES | 2009 |
|
RU2523552C2 |
| GROWTH-STIMULATING COMPOSITION | 2000 |
|
RU2242228C2 |
